EraGen Announces Appointment of Vader As Vice President, Quality, Regulatory and Clinical Affairs
Posted on: Thursday, 12 June 2008, 15:00 CDT
EraGen Biosciences Inc. today announced the appointment of Randal Vader as vice president, quality, regulatory and clinical affairs.
Mr. Vader brings more than two decades of quality systems, and regulatory and clinical affairs leadership to his new role at EraGen. His experience includes quality system creation, implementation and improvement; clinical study design and execution; and regulatory strategy and compliance, including FDA submissions.
Mr. Vader was most recently lead director of quality and regulatory for Philips Medical Systems' Radiation Oncology Systems business unit. While at Philips, Mr. Vader was responsible for all quality systems and regulatory matters at its facilities in Madison, Wis.; Milpitas, Calif.; and Cleveland.
Prior to joining Philips, Mr. Vader led the quality, regulatory and clinical affairs function at Inovise Medical Inc., a cardiac diagnostic device company. He joined Inovise after serving as an associate director for regulatory affairs and quality systems at Focus Diagnostics Inc., which was subsequently purchased by Quest Diagnostics. Mr. Vader also has held management positions in quality, regulatory and clinical affairs at VIA Medical, Quidel Corp. and Sulzer Medica.
"EraGen is pleased to welcome Randy to our team at this important time in the company's development," said Irene Hrusovsky, M.D., president and chief executive of EraGen. "As we continue to execute our growth strategy, FDA submissions will become an increasingly important part of EraGen's product commercialization efforts. Randy has a wealth of experience with the rapidly-evolving landscape of in vitro diagnostic regulation. He will make an immediate contribution to the company and our management team."
"I am delighted to be joining a company with such a strong commitment to quality and regulatory compliance," Mr. Vader said. "I look forward to working with the great team at EraGen to capture the significant opportunities that exist for the company in the rapidly-growing molecular diagnostics market."
Mr. Vader earned a bachelor of science degree in biology from San Diego State University.
About EraGen BioSciences
EraGen BioSciences Inc. develops, manufactures and markets molecular diagnostic products that are driving the new era in diagnostics. The company's in-market and pipeline products, based on its patented MultiCode(R) platform chemistry, are the next generation of DNA-based testing for the early, accurate detection of infectious diseases, genetic-based conditions and cancer. EraGen's menu of easy-to-use, accurate and robust products positions the company for leadership in molecular diagnostic development and commercialization. For more information, visit the EraGen website at www.eragen.com.
Source: Business Wire
Related Articles
- Ortho Clinical Diagnostics Receives FDA Approval for First Anti-HIV 1+2 Test for Use on Random Access, Integrated Laboratory Testing System
- Ortho Clinical Diagnostics Launches 24-Hour Remote Monitoring Center
- Magellan Diagnostic Businesses to Feature Automated Systems and Diagnostic Tests at Clinical Lab Expo
- Ortho Clinical Diagnostics Sponsors Five Points of Life Ride in Raritan
- Cinpathogen Provides Clinical Diagnostic Consulting Services to Shanghai Area Hospitals
- Ortho-Clinical Diagnostics Receives FDA Approval for First Blood-Screening Test for Chagas' Disease
- Exagen Diagnostics Names Luc Van Hove Vice President, Quality, Regulatory, Medical Affairs and Chief Medical Officer
- Luminex Corporation Awarded Frost & Sullivan 2005 Clinical Diagnostics Technology of the Year
- OraSure Receives HCV Patent License From Ortho-Clinical Diagnostics and Chiron Corporation; OraSure to Develop and Commercialize Rapid HCV Test
 |
 |
User Comments (0)
RSS Feeds